Literature DB >> 3707110

Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.

C J Hackbarth, H F Chambers, M A Sande.   

Abstract

Because rifampin-resistant strains of Staphylococcus aureus emerge during monotherapy with this drug, a search was made for potentially useful companion drugs. Bactericidal titers of spiked serum were determined, and time kill studies were performed for 10 strains of methicillin-susceptible S. aureus. We tested rifampin in combination with nafcillin, vancomycin, clindamycin, pefloxacin, ciprofloxacin, trimethoprim, teicoplanin, or erythromycin. The bactericidal activity of nafcillin, vancomycin, and teicoplanin was significantly reduced (P less than 0.05) when rifampin was added to the drug regimen. In contrast, the addition of rifampin to clindamycin or erythromycin significantly increased bactericidal activity as measured by both bactericidal titers in serum and 6-h killing rates (P less than 0.02). Bactericidal activity in serum was also increased by the addition of rifampin to trimethoprim, but rifampin-resistant strains emerged with this combination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707110      PMCID: PMC180452          DOI: 10.1128/AAC.29.4.611

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies.

Authors:  G L Mandell; T K Vest
Journal:  J Infect Dis       Date:  1972-05       Impact factor: 5.226

2.  Interaction between vancomycin and rifampin against Staphylococcus aureus.

Authors:  C Watanakunakorn; J C Guerriero
Journal:  Antimicrob Agents Chemother       Date:  1981-06       Impact factor: 5.191

3.  Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance.

Authors:  G L Mandell; D R Moorman
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

4.  In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.

Authors:  D L Van Caekenberghe; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  A S Bayer; J O Morrison
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

6.  In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus.

Authors:  C U Tuazon; M Y Lin; J N Sheagren
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

7.  In vitro antibacterial activity of three new quinolone derivatives: rosoxacin, norfloxacin, pefloxacin.

Authors:  M O Husson; D Izard; H Leclerc
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1984-12

8.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  Measles immunization in Iran.

Authors:  H Mirchamsy
Journal:  Rev Infect Dis       Date:  1983 May-Jun

10.  Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis.

Authors:  M P Weinstein; C W Stratton; A Ackley; H B Hawley; P A Robinson; B D Fisher; D V Alcid; D S Stephens; L B Reller
Journal:  Am J Med       Date:  1985-02       Impact factor: 4.965

  10 in total
  33 in total

1.  In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations.

Authors:  Samuel A Shelburne; Daniel M Musher; Kristina Hulten; Heather Ceasar; Michael Y Lu; Imran Bhaila; Richard J Hamill
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Emergence and spread of rifampicin-resistant, methicillin-resistant Staphylococcus aureus during vancomycin-rifampicin combination therapy in an intensive care unit.

Authors:  O Ju; M Woolley; D Gordon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

3.  Intracardiac device and prosthetic infections: What do we know?

Authors:  Lynn B Johnston; John M Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-07       Impact factor: 2.471

4.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

Review 5.  Synergy and antagonism of combinations with quinolones.

Authors:  H C Neu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

6.  In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  D Bahl; D A Miller; I Leviton; P Gialanella; M J Wolin; W Liu; R Perkins; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 7.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 8.  Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Authors:  H C Neu
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.

Authors:  Catherine Clark; Lois M Ednie; Gengrong Lin; Kathy Smith; Klaudia Kosowska-Shick; Pamela McGhee; Bonifacio Dewasse; Linda Beachel; Patrick Caspers; Bérangère Gaucher; Gürkan Mert; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

10.  The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.

Authors:  Andrew E Simor; Mark Loeb
Journal:  Can J Infect Dis       Date:  2004-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.